Browse complete Report Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets Report
Browse all CHI Healthtech Market Research Reports
Epigenetics is a rapidly growing field with promising implications for treatment of cancer and potentially other diseases. Research interest in epigenetics has exploded in recent years, and considerable progress has been made in the commercialization of discoveries in this field.
Discussed in this Report:
- Diagnostic applications of epigenetics
- Diseases and conditions targeted by current and emerging epigenetic-based therapies
- Companies marketing and/or developing therapies that target epigenetic changes within the disease process
- Current and projected markets for epigenetic diagnostic and therapeutic products
- Strategic issues and major challenges for developers of epigenetic-based products
- Thought-leader interviews
Many companies have recognized the potential benefits of epigenetic-based diagnostic and therapeutic products. Two epigenetic tests for colorectal cancer screening are CE-marked and available in Europe, and a number of epigenetic tests are available through clinical laboratories in the United States as laboratory developed tests (LDTs). Four epigenetic drugs have now been approved by the US FDA.
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Original Source: DNA Methylation Market, HDAC Inhibitors Market
Buy Now: Market Research
